Arvinas (ARVN) Net Cash Flow (2017 - 2026)
Arvinas (ARVN) recorded quarterly Net Cash Flow of -$55.6 million in Q1 2026, down 234.3% quarter-over-quarter from $41.4 million in Q4 2025, and down 185.13% on a YoY basis from $65.3 million in Q1 2025.
Arvinas (ARVN) Net Cash Flow (2017 - 2026) Analysis & Trends
Arvinas' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$55.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 185.13% year-over-year to -$55.6 million; the TTM figure through Mar 2026 stood at $6.3 million (up 150.4% YoY), while the FY2025 annual figure was $42.4 million, up 119.57% from the prior year.
- Net Cash Flow was -$55.6 million for Q1 2026 at Arvinas, down from $41.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $198.0 million in Q4 2023 to a low of -$223.7 million in Q1 2024.
- Historically, Net Cash Flow has averaged -$1.5 million across 5 years, with a median of $15.3 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow jumped 485.96% in 2023, then slumped 557.46% in 2024.
- A 5-year view of Net Cash Flow shows it stood at -$51.3 million in 2022, then surged by 485.96% to $198.0 million in 2023, then plunged by 92.27% to $15.3 million in 2024, then soared by 170.59% to $41.4 million in 2025, then sank by 234.3% to -$55.6 million in 2026.
- The last three Net Cash Flow figures came in at -$55.6 million (Q1 2026), $41.4 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -55.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.60 Mn |
| Mar 31, 2026 | -55.60 Mn |
| Dec 31, 2025 | 41.40 Mn |
| Dec 31, 2025 | 41.40 Mn |
| Sep 30, 2025 | -13.40 Mn |
| Sep 30, 2025 | -13.40 Mn |
| Jun 30, 2025 | 33.90 Mn |
| Jun 30, 2025 | 33.90 Mn |
| Mar 31, 2025 | -19.50 Mn |
| Mar 31, 2025 | -19.50 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | -75.10 Mn |
| Sep 30, 2024 | -75.10 Mn |
| Jun 30, 2024 | 66.80 Mn |
| Jun 30, 2024 | 66.80 Mn |
| Mar 31, 2024 | -223.70 Mn |
| Mar 31, 2024 | -223.70 Mn |
| Dec 31, 2023 | 198.00 Mn |
| Dec 31, 2023 | 198.00 Mn |